Printer Friendly

PRA International Names Phase Forward's OutcomeLogix[TM] as Preferred Late Phase Solution.

Solution Complements CRO's Operational and Therapeutic Expertise

WALTHAM, Mass. -- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that PRA International has named Phase Forward's OutcomeLogix[TM] as its preferred late phase solution provider.

"With the extensive experience of our late phase services group, we have long understood the need for technology solutions focused on the specific needs of late phase and patient reported outcomes studies," said Maria Harrison, vice president, Late Phase Services, PRA. "We are delighted with the success we have achieved over the last year integrating OutcomeLogix with our innovative late phase and registry study models across sponsor projects. We look forward to our mutual continued success."

"We are pleased with the success that PRA International has achieved with OutcomeLogix to date and look forward to broadening our relationship," said Scott Dixon, vice president, OutcomeLogix Group, Phase Forward. "We value our relationship with PRA and are committed to working together to deliver best-of-breed solutions to the marketplace."

Phase Forward and PRA International will be jointly presenting at CBI's Bio/Pharmaceutical and Medical Device Registries and Post-Approval Studies Congress on the topic "Utilizing Technology to Promote Risk Management and Enhance REMS Compliance" during a luncheon at 12:20 p.m. on Wednesday, September 23.

About PRA International

PRA's Late Phase Services group supports global and regional Post-approval studies. In the past three years, PRA has conducted over 160 late phase studies with nearly 18,000 sites and more than 187,000 patients in 42 countries. Late Phase Services assists sponsors with the Post-Marketing process by planning and conducting Safety-Surveillance studies, Registries, Large Simple Trials, Retrospective Studies and Restricted Access Programs. PRA supports its operational teams with industry-leading strategic, scientific, medical, and epidemiological experts. Our international management team leads a truly global late phase team with centralized locations in Horsham, PA, USA and Mannheim, Germany.

PRA International conducts clinical trials in more than 65 countries across 6 continents and provides services through all phases of clinical development. PRA performs studies in all therapeutic areas and has supported over 2,100 clinical trials through its 36 global offices.

PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT, enable our project teams to deliver consistent and on-time performance for our clients. This unique PRA philosophy -- THE PERSONAL ELEMENT -- recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.

To learn more about PRA International, please visit www.PRAinternational.com, email Endpoints@PRAintl.com or call our Global Headquarters at +1 (919) 786-8200.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward's products and services, demand for Phase Forward's products and services, future business and operations plans of a Phase Forward customer, and the ability of Phase Forward's customers to realize benefits from the use of Phase Forward's products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward's customers to realize benefits from the use of its products and services, the possibility that customers' needs or plans may change over time, the possibility that the level of demand for Phase Forward's products and services may vary, regulatory changes and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1U1MA
Date:Sep 22, 2009
Words:843
Previous Article:Tenet Announces Pricing of Its Mandatory Convertible Preferred Stock Offering and Repurchase of $300 Million of Its Outstanding Notes.
Next Article:Bayer Honored Again as a Top Company for Working Mothers.


Related Articles
Pro-Pharmaceuticals Retains PRA International for Clinical Trial In Cancer Patients.
Pro-Pharmaceuticals Engages WorldCare Clinical to Enhance and Accelerate the Phase II Trial.
Anaclim, LLC and Maaguzi, LLC Form a Collaboration That Will Maximize Services Available for Patient Related Health Outcome Data.
Phase Forward Reports Second Quarter 2009 Results.
Phase Forward and SGS Life Science Services Sign Multi-Year, Multi-Million Dollar Agreement.
Phase Forward Completes Acquisition of Covance's Interactive Voice and Web Response Services Business.
Phase Forward Teams with PharmaNet Development Group.
PRA International Achieves Highest Accreditation in Medidata CRO Program.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters